Cross-modal fusion of cytomorphology and 18F-FDG PET/CT for non-invasive bone marrow immune microenvironment decoding in multiple myeloma - Scorecard - MDSpire
Advertisement
Cross-modal fusion of cytomorphology and 18F-FDG PET/CT for non-invasive bone marrow immune microenvironment decoding in multiple myeloma
Clinical Scorecard: Integration of Cytomorphological Analysis and 18F-FDG PET/CT Imaging for Non-Invasive Assessment of the Bone Marrow Immune Microenvironment in Multiple Myeloma
At a Glance
Category
Detail
Condition
Multiple Myeloma
Key Mechanisms
Bone marrow immune microenvironment influences treatment response and disease progression.
Target Population
Patients with newly diagnosed multiple myeloma.
Care Setting
Clinical diagnostic settings utilizing routine imaging and cytomorphological analysis.
Key Highlights
ImmunoCast-MM integrates cytomorphological analysis and PET/CT imaging.
The framework generates an Immune Dysfunction Index (IDI) for assessing immune competence.
Correlation of cytomorphologic indices with flow cytometric measurements was significant (Spearman ρ values of 0.68–0.81).
Adding IDI to conventional risk markers improved prognostic accuracy.
Identified immune-competent and immune-exhausted archetypes associated with treatment response.
Guideline-Based Recommendations
Diagnosis
Utilize Wright–Giemsa-stained bone marrow aspirate smears and 18F-FDG PET/CT for comprehensive assessment.
Management
Consider immune competence alongside tumor burden in treatment planning.
Monitoring & Follow-up
Monitor changes in the immune microenvironment as part of disease progression assessment.
Risks
Patients with pre-treatment NK cell depletion may have poorer responses to immunotherapy.
Patient & Prescribing Data
Newly diagnosed multiple myeloma patients.
Immune profiling may guide immunotherapy selection and stratification.
Clinical Best Practices
Incorporate non-invasive immune profiling into routine diagnostic workflows.
Utilize the Immune Dysfunction Index for enhanced risk assessment.
